Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.

September 8, 2020
SanofiSanofi today announced that the global Phase 3 trial investigating intravenously administered Kevzara® (sarilumab) at a dose of 200 mg or 400 mg[1] in severely or critically ill[2] patients hospitalized with COVID-19 did not meet its primary endpoint and key secondary endpoint[3] when Kevzara was compared to placebo added to usual hospital care.